PriceWaterhouseCoopers asks a really big question: which Asian country is the best place to find an outsourcing partner or to build a new biomedical facility; tainted infant formula is the latest iteration of product-safety stories from China; China Biologic Products will begin a clinical trial of its new Human Coagulation Factor VIII product (FVIII); Sinovac Biotech licensed a Ukraine vaccine manufacturer to conduct trials of its hepatitis A vaccine; Xel Pharma is developing a transdermal patch to deliver a TCM drug for Alzheimer’s disease; another TCM medication is being tested by Phytomedics for rheumatoid arthritis; China Sky One Medical completed the first phase of examinations for the CE mark; China Biopharma completed a 1-for-100 reverse stock split; and China Pharma Holdings forecast a 40% to 45% increase in its Q3 revenues.  More details... Stock Symbols: (OTCBB: CBPO) (AMEX: SVA) (NSDQ: CSKI) (OTCBB: CHBO) (OTCBB: CPHI)